Search filters

List of works by Matteo Carlino

(18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma.

scientific article published on 14 September 2012

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

scientific article published oln 16 November 2016

A multicenter analysis of immune checkpoint inhibitors as adjuvant therapy following treatment of isolated brain metastasis

scientific article published on 23 November 2020

A phase 1b/2 study of the BRAF inhibitor encorafenib plus the MEK inhibitor binimetinib in patients with BRAF V600E/K-mutant solid tumors

scientific article published on 15 July 2020

Abstract 4864: Targeted melanoma therapies as radiosensitizers

scholarly article

Abstract 5025: Immune expression profiling of MAPK inhibitor resistant tumors based upon mechanisms of resistance

Abstract 81: The association between melanoma liver metastases (mets) and the systemic anti-tumor immune profile

scientific article published on 4 April 2023

Abstract CT068: A Phase I trial of LXS196, a novel PKC inhibitor for metastatic uveal melanoma

scholarly article

Acute Truncal Lymphedema Secondary to Axillary Metastatic Melanoma Presenting Like Cellulitis

scientific article

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

scientific article published on 15 April 2018

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial ⬇️

journal article from 'The Lancet Oncology' published in 2021

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations.

scientific article

An Online Learning Module to Increase Self-Efficacy and Involvement in Care for Patients With Advanced Lung Cancer: Research Protocol

scientific article published on 08 August 2016

Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma

scientific article published on 29 November 2019

Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA

scientific article published on 12 April 2022

Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma.

scientific article

Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma.

scientific article published on January 2015

Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.

scientific article published on 8 February 2018

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial

scientific article published on 02 January 2020

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials

scientific article published on 16 July 2020

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.

scientific article published on 12 February 2018

Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma.

scientific article published on 19 January 2016

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

scientific article published on 24 January 2014

BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting

Biology and treatment of BRAF mutant metastatic melanoma

scientific article published on 12 February 2016

Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies

scientific article published on 01 August 2016

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series

scientific article

Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy

scientific article published on 16 October 2020

Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy

article

Circulating tumor DNA (ctDNA) using Guardant360 to predict response in BRAF V600 WT metastatic melanoma (MM) patients (pts) receiving immune checkpoint inhibitors (ICI).

scientific article published on 25 May 2020

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma

scientific article published on 22 September 2015

Circulating tumour DNA and melanoma survival: A systematic literature review and meta-analysis

scientific article published on 27 November 2020

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing

scientific article

Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors

scientific article published on 28 July 2015

Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab

scientific article published on 01 November 2020

Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients

scientific article published on 16 October 2019

Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

scientific article published on 06 June 2019

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

scientific article (publication date: 2 July 2015)

Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma

scientific article published on 02 November 2019

Corrigendum to “Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*” [Eur J Cancer 91 (2018) 116–124]

scientific article published on 13 March 2018

Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma

scientific article published on 28 January 2020

Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma

scientific article published on 22 July 2015

Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.

scientific article published on 12 January 2016

Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA

scientific article published on 10 August 2020

Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies

scientific article published on 03 November 2020

Differences in immune profiles of metastatic melanoma patients treated with anti-CTLA-4 and anti-PD-1 combined immunotherapy. ⬇️

scholarly article

Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.

scientific article published on 15 January 2014

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy

scientific article published on 01 February 2019

Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma

scientific article published on 10 January 2019

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

scientific article published on 24 April 2012

Dosing of BRAK and MEK Inhibitors in Melanoma: No Point in Taking a Break

scientific article published on 01 December 2020

Durability of response to immune checkpoint inhibitors (ICI) in metastatic Merkel cell carcinoma (mMCC) after treatment cessation.

scientific article published on 02 June 2021

Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.

scientific article published on 16 May 2017

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.

scientific article published on 18 May 2017

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

scientific article published on 17 June 2019

Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial

scientific article published on 30 July 2020

Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients

scientific article published on 10 November 2017

Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma

scientific article published on 3 April 2015

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

article

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

scientific article published on 28 September 2019

High response rate to PD-1 blockade in desmoplastic melanomas

scientific article published on 10 January 2018

Hypermethylation of Circulating Free DNA in Cutaneous Melanoma ⬇️

scholarly article

Immune Checkpoint Inhibitor Toxicity

article

Immune checkpoint inhibitors in melanoma

scientific article published on 10 August 2015

Immunotherapy of Ipilimumab and Nivolumab in patients with advanced neuroendocrine tumours: a subgroup analysis of the CA209-538 clinical trial for rare cancers

scientific article published on 12 June 2020

Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma

scientific article published on 01 September 2018

Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies

scientific article published on 03 March 2019

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.

scientific article published on 2 December 2014

Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients

scientific article published on 31 October 2018

Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma

scientific article published on 06 January 2014

Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?

scientific article published on 23 June 2016

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

scientific article

KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma

scientific article published on 24 December 2019

Long-Term Follow-Up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients With Advanced Melanoma: KEYNOTE-029 Part 1B

scientific article published on 30 June 2020

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma

scientific article published on 23 December 2020

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

scientific article published on 18 September 2020

Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors

scientific article published on 22 April 2020

Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia

scientific article published on 15 November 2020

Melanoma brain metastases: the outcome of whole brain radiation therapy in the era of effective systemic therapy

scientific article published in September 2021

Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis

scientific article published on 22 October 2020

Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma.

scientific article published on 24 November 2017

Miller Fisher Syndrome Associated With Immunotherapy for Metastatic Melanoma

scientific article published on 27 May 2018

Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis

scientific article published on 31 July 2020

Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors

scientific article

Musculoskeletal immune-related adverse events with use of checkpoint inhibitors in malignancy

scientific article published on 02 November 2020

Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients.

scientific article published on 4 August 2017

New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma

scientific article published on 12 May 2014

Non-coding RNA and immune-checkpoint inhibitors: friends or foes?

scientific article published on 07 May 2020

OTHR-08. PREDICTION OF RISK OF CENTRAL NERVOUS SYSTEM METASTASIS FOR AJCC 8TH EDITION STAGE III MELANOMA PATIENTS

scholarly article

Oncogenic signaling in uveal melanoma.

scientific article published on 8 May 2018

Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists.

scientific article published on December 2016

Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial

scientific article published on 07 August 2018

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

scientific article published on 11 September 2017

PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges.

scientific article published on June 2016

PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors

scientific article

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

scientific article

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

scientific article

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

scientific article published on 22 July 2019

Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis.

scientific article published on 10 November 2016

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma

scientific article published on 13 June 2017

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

scientific article published on 19 September 2016

Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.

scientific article

Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients

scientific article published on 10 March 2020

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma

scientific article published on 11 June 2019

Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling

scientific article published in 2022

Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

scientific article published on 01 August 2019

Radiological manifestations of immune-related adverse effects observed in patients with melanoma undergoing immunotherapy.

scientific article

Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study

scientific article

Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.

scientific article published on 21 March 2017

Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy.

scientific article

Resistance to c-Kit inhibitors in melanoma: insights for future therapies

scientific article

Safety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma

scientific article published on 19 October 2017

Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion

scientific article published on 07 November 2019

Sentinel node biopsy for melanoma: The medical oncology perspective

Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy

scientific article published on 04 October 2019

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.

scientific article published on 17 July 2017

Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma

Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events

scientific article published on 21 June 2019

Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy.

scientific article published on 26 December 2017

Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations

scientific article published on 03 October 2019

Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma.

scientific article published on 28 August 2015

The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma

scientific article published on 29 November 2019

The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma

scientific article published on 18 March 2023

Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition

scientific article published on 20 April 2020

Treatment of melanoma brain metastases: a new paradigm.

scientific article published on March 2012

Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma

scientific article published on 14 November 2020

Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites

scientific article published in September 2022

Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours

scientific article published on 15 May 2020

Paulina is supported by:

About Paulina

Help